ecancermedicalscience

Case Report

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib

30 May 2022
Shubham Tomar, Lakhan Kashyap, Akhil Kapoor

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant syndrome associated with fumarate hydratase (FH) gene mutation leading to defective DNA double-strand break repair mechanism. Although these tumours have an aggressive presentation, they respond well to targeted therapy with fewer adverse effects. Here we present a case of a 42-year-old female having isolated renal cell carcinoma, papillary type 2, carrying a mutation in the FH gene without cutaneous and uterine involvement. Her tumour responded well to erlotinib and bevacizumab combination and she was on treatment for 23 months. This report adds to the current literature and can help to define treatment protocols for HLRCC.

Related Articles

Jessica O Esangbedo, Rachael O Oduyemi, Damilare Aduroja, Yetunde O Tola, Olajumoke Dele-Alonge, Emmanuel O Adesuyi, Michael O Ajiboye, Oluwadamilare Akingbade
Olatunde Olaniyi Abiodun Oluwafemi, Eberechukwu Uchime Kasiemobi, Mustapha Babatunde, Bankole Kofi Adedeji, Oyelayo Oluwaseun Olaoluwa, Ismaheel Aderogba Azeez, Ezekpo Okechukwu Obumneme
Chase Peng Yun Ng, Moira Hegyi, Grant Lewison, Tania Pastrana, Eve Namisango, James Cleary, Barbara Hasties, Eric Kabisa, Helena Musau, Kathryn Spangenberg, Paola Ruiz, Zipporah Ali, Mertixell Mallafre-Larrosa, Alfredo Polo, Julie Torode, Ajay Aggarwal, Richard Sullivan, Mevhibe Hocaoglu